HIV Infection Clinical Trial
Official title:
Evaluation of the Safety of a Polyvalent Vaccinia Virus-HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults
This is a research study to evaluate the safety of a vaccine to protect people from HIV
infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune
Deficiency Syndrome). AIDS is one of the most serious viral infections of our time. It is
believed that all persons who contract HIV will eventually develop AIDS. Because of this, we
are trying to develop new ways to prevent infection with HIV.
The vaccine that will be tested in this study has been prepared from a small part of the
HIV. The part of the HIV used in this vaccine is the "envelope" or coating part of the
virus. In this study, researchers will evaluate how well the vaccine is tolerated, how much
vaccine should be given, and determine if any side effects occur in response to the
vaccination.
This is a research study to evaluate the safety of a vaccine to protect people from HIV
infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune
Deficiency Syndrome). AIDS is one of the most serious viral infections of our time. It is
believed that all persons who contract HIV will eventually develop AIDS. Because of this, we
are trying to develop new ways to prevent infection with HIV.
Vaccines have been very successful in preventing or decreasing the symptoms of a number of
other viral infections such as hepatitis B, polio, and measles. Viral vaccines work by
causing a person's immune system to make antibodies and immune cells against the virus or to
"respond" to the virus. Because of the success with other viral infections, scientists are
trying to develop a successful vaccine for HIV.
The vaccine that will be tested in this study has been prepared from a small part of the
HIV. The part of the HIV used in this vaccine is the "envelope" or coating part of the
virus. Because only this one part of the virus is used in the vaccine, the vaccine cannot
cause HIV infection. The "envelope" part of HIV has been put into another virus, the
vaccinia virus. The vaccinia virus has been used as a vaccine for many decades in millions
of people and is the vaccine that eliminated the disease known as smallpox (i.e. smallpox
vaccine). The smallpox vaccine is a licensed and effective vaccine. Making a new vaccine by
putting part of a different virus into the smallpox vaccine (also known as vaccinia virus)
is called a "recombinant" vaccinia virus vaccine. Our new recombinant vaccine product is
called PolyEnv1. In this study, researchers will evaluate how well the vaccine is tolerated,
how much vaccine should be given, and determine if any side effects occur in response to the
vaccination.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |